The history of FEIBA: a lifetime of success in the treatment of haemophilia complicated by an inhibitor Négrier.C, et al. - The development of alloantibodies that inhibit the function of factor VIII (FVIII) or factor IX (FIX) is the most serious complication associated with the treatment of haemophilia. Bleeding events in patients with high-titre inhibitors generally cannot be managed with factor replacement therapy and require alternative strategies for haemostatic support [more...]
